☆ 4.6 Article

The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura

BRITISH JOURNAL OF HAEMATOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Obinutuzumab-related adverse events: A systematic review and meta-analysis

Irina Amitai et al.

Summary: Obinutuzumab shows superior clinical efficacy over Rituximab in follicular lymphoma and chronic lymphocytic leukemia, but with higher toxicity, including significantly increased risk of grade 3-4 adverse events. Physicians need to consider the balance between clinical benefits and potential toxicity when using this agent.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker et al.

Summary: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal disease caused by severe deficiency of ADAMTS13, and standardized definitions of response and exacerbation primarily based on platelet count have been modified to incorporate ADAMTS13 activity and the effects of anti-VWF therapy. The revised definitions distinguish between clinical and ADAMTS13 remission and relapse, and are benchmarked against not only the timing of discontinuation of therapeutic plasma exchange (TPE) but also that of anti-VWF therapy. Validation of the revised definitions is retrospective, with discussion on the clinical implications of the updated outcome definitions.

BLOOD (2021)

添加到收藏夹

Article Medicine, General & Internal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Rituximab Hypersensitivity: From Clinical Presentation to Management

Ghada E. Fouda et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Letter Hematology

Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies

Chiara Vendramin et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

添加到收藏夹

Letter Hematology

Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab

Judith Robertz et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study

Guillaume Bayer et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Letter Rheumatology

Successful treatment of systemic lupus erythematosus-related refractory autoimmune hemolytic anemia with ofatumumab

Antoine Poulet et al.

LUPUS (2019)

添加到收藏夹

Letter Medicine, General & Internal

More on Ofatumumab for TTP

Fleur Cohen Aubart et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

R. Marcus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Hematology

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens

John-Paul Westwood et al.

BLOOD ADVANCES (2017)

添加到收藏夹

Article Hematology

Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study

Ygal Benhamou et al.

AMERICAN JOURNAL OF HEMATOLOGY (2016)

添加到收藏夹

Review Rheumatology

Rituximab-induced serum sickness: A systematic review

Paras Karmacharya et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)

添加到收藏夹

Article Hematology

Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse

J-P. Westwood et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.